iTeos Therapeutics
iTeos Therapeutics Logo
About iTeos Therapeutics
iTeos Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of immuno-oncology therapeutics for cancer patients. Its pipeline includes antibody and small molecule candidates such as belrestotug, an antagonist of TIGIT, inupadenant, a next-generation A2AR antagonist, and EOS-984, a small molecule targeting ENT1. The company conducts clinical trials in the United States and Belgium, aiming to advance innovative therapies that address immunosuppressive pathways in the tumor microenvironment.
Address
321 Arsenal Street, Suite 301 Building 312
Watertown, 02472
United States
Year founded
2019
Number of employees
100-200
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
